Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease-Reference-Cited by-同舟云学术

Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease

Published:2018-03 Issue:3 Volume:24 Page:555-562
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Lee Stephanie J.^ORCID,Nguyen Tam D.,Onstad Lynn,Bar Merav,Krakow Elizabeth F.,Salit Rachel B.,Carpenter Paul A.,Rodrigues Morgani,Hall A. Marcie,Storer Barry E.,Martin Paul J.,Flowers Mary E.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference18 articles.

1. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European Group for Blood and Marrow Transplantation (EBMT);Champlin;Blood,2000

2. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation;Arora;Biol Blood Marrow Transplant,2016

3. Chronic graft-versus-host disease;Lee;Biol Blood Marrow Transplant,2003

4. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation;Inamoto;Blood,2011

5. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants;Feng;JAMA,2012

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease;Contemporary Clinical Trials;2024-10

2. Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation;Blood Advances;2024-08-30

3. Graft Versus Host Disease: Management Issues in the Intensive Care Unit;Journal of Intensive Care Medicine;2024-08-07

4. An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD;American Journal of Hematology;2024-06-27

5. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease;Transplantation and Cellular Therapy;2024-06